Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constantin Lapa

Showing results (171-180 of 317) with videos related to

Pageof 32
Sort By:
Scientific Reports|December 6, 2018
Left Ventricular Diastolic Dysfunction in a Rat Model of Diabetic Cardiomyopathy using ECG-gated <sup>18</sup>F-FDG PETRudolf A Werner, Christoph Eissler, Nobuyuki Hayakawa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2024
[<sup>68</sup>Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case SeriesAlex J Poot, Constantin Lapa, Wolfgang A Weber, et al.
Leukemia & Lymphoma|July 8, 2022
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agentsAnna Bögelein, Antje Stolzenburg, Patrick Eiring, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
CCK<sub>2</sub> Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [<sup>68</sup>Ga]Ga-DOTA-CCK-66Oliver Viering, Thomas Günther, Nadine Holzleitner, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Oncotarget|June 4, 2016
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathyRudolf A Werner, Seval Beykan, Takahiro Higuchi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2026
Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center studySong Xue, Holger Einspieler, Sijie Wen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
SSTR Antagonists as Theranostic Option in Merkel Cell CarcinomaMalte Kircher, Adriana Amerein, Mareike Augustin, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Theranostics|January 8, 2019
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Rudolf A Werner, Alexander Weich, Malte Kircher, et al.
Pageof 32

Showing results (171-180 of 317) with videos related to

Sort By:
Pageof 32
Scientific Reports|December 6, 2018
Left Ventricular Diastolic Dysfunction in a Rat Model of Diabetic Cardiomyopathy using ECG-gated <sup>18</sup>F-FDG PETRudolf A Werner, Christoph Eissler, Nobuyuki Hayakawa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2024
[<sup>68</sup>Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case SeriesAlex J Poot, Constantin Lapa, Wolfgang A Weber, et al.
Leukemia & Lymphoma|July 8, 2022
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agentsAnna Bögelein, Antje Stolzenburg, Patrick Eiring, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
CCK<sub>2</sub> Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [<sup>68</sup>Ga]Ga-DOTA-CCK-66Oliver Viering, Thomas Günther, Nadine Holzleitner, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Oncotarget|June 4, 2016
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathyRudolf A Werner, Seval Beykan, Takahiro Higuchi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2026
Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center studySong Xue, Holger Einspieler, Sijie Wen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
SSTR Antagonists as Theranostic Option in Merkel Cell CarcinomaMalte Kircher, Adriana Amerein, Mareike Augustin, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Theranostics|January 8, 2019
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Rudolf A Werner, Alexander Weich, Malte Kircher, et al.
Pageof 32